Bronchiectasis - Pipeline Review, H2 2016

Date: October 26, 2016
Pages: 84
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B301B307562EN
Leaflet:

Download PDF Leaflet

Bronchiectasis - Pipeline Review, H2 2016
Bronchiectasis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis - Pipeline Review, H2 2016, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.

Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 4 and 3 respectively for Bronchiectasis.

Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Bronchiectasis Overview
Therapeutics Development
Pipeline Products for Bronchiectasis - Overview
Bronchiectasis - Therapeutics under Development by Companies
Bronchiectasis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bronchiectasis - Products under Development by Companies
Bronchiectasis - Companies Involved in Therapeutics Development
Alitair Pharmaceuticals, Inc.
Bayer AG
Grifols, S.A.
Insmed Incorporated
Kamada Ltd.
Polyphor Ltd.
Raptor Pharmaceutical Corp.
Recipharm AB
Savara Inc.
Vertex Pharmaceuticals Incorporated
Bronchiectasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
alpha-1 proteinase inhibitor (human) second generation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amikacin sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARD-3150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ciprofloxacin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
doxofylline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erdosteine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leukotriene-B4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levofloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
POL-6014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
POL-7080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vancomycin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VX-371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bronchiectasis - Dormant Projects
Bronchiectasis - Discontinued Products
Bronchiectasis - Product Development Milestones
Featured News & Press Releases
Oct 18, 2016: Bayer to Present Data in Non-Cystic Fibrosis Bronchiectasis at the 2016 Annual Meeting of the American College of Chest Physicians
Sep 22, 2016: Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients
Mar 17, 2016: Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency
Mar 16, 2016: Raptor Announces Qualified Infectious Disease Product Designation for MP-376, Inhaled Levofloxacin
Jan 05, 2016: Aradigm to Host Corporate Update Conference Call on January 6
Oct 13, 2015: Aradigm Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis
Sep 22, 2015: Aradigm Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
Apr 16, 2015: Aradigm to Host Key Opinion Leader Breakfast and Webcast on April 23 in New York City
Jan 14, 2015: Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia
Nov 24, 2014: FDA Grants QIDP Designation to Bayer's Ciprofloxacin Dry Powder for Inhalation
Sep 04, 2014: FDA Grants Fast Track Designation to Aradigm’s Pulmaquin for Non-Cystic Fibrosis Bronchiectasis
Jun 23, 2014: Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
Jun 03, 2014: Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis
May 20, 2014: FDA Grants QIDP Designation to Aradigm’s Inhaled Antibiotic
Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 84

LIST OF TABLES

Number of Products under Development for Bronchiectasis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Bronchiectasis - Pipeline by Alitair Pharmaceuticals, Inc., H2 2016
Bronchiectasis - Pipeline by Bayer AG, H2 2016
Bronchiectasis - Pipeline by Grifols, S.A., H2 2016
Bronchiectasis - Pipeline by Insmed Incorporated, H2 2016
Bronchiectasis - Pipeline by Kamada Ltd., H2 2016
Bronchiectasis - Pipeline by Polyphor Ltd., H2 2016
Bronchiectasis - Pipeline by Raptor Pharmaceutical Corp., H2 2016
Bronchiectasis - Pipeline by Recipharm AB, H2 2016
Bronchiectasis - Pipeline by Savara Inc., H2 2016
Bronchiectasis - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Bronchiectasis - Dormant Projects, H2 2016
Bronchiectasis - Discontinued Products, H2 2016 69

LIST OF FIGURES

Number of Products under Development for Bronchiectasis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Bronchiectasis - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 88 pages
Insulin Resistance - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 49 pages
Primary Biliary Cirrhosis - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 90 pages
Warts - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 85 pages

Ask Your Question

Bronchiectasis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: